Similar companies
| Company | Transaction Value | |
|---|---|---|
 |
OcugenOCGN |
-$5.5M |
 |
Gilead SciencesGILD |
-$4.04B |
 |
AmgenAMGN |
-$189M |
 |
Editas MedicineEDIT |
-$7M |
 |
Crispr TherapeuticsCRSP |
-$177M |
Are Lexicon Pharmaceuticals Insiders Buying or Selling?
Lexicon Pharmaceuticals (LXRX) has had no reported insider transactions in the past 90 days. The most recent was RAYMOND DEBBANE, who bought 2,000 shares at $1.49 on February 25, 2026.
Insider trading patterns can signal confidence or concern from the people who know the company best. AltIndex tracks insider transactions as one of 25+ alternative data signals in the LXRX AI Score. For government officials trading this stock, see LXRX congressional trading.
Who’s Trading Lexicon Pharmaceuticals Stock?
| Insider | Activity | Trades | Last Trade |
|---|---|---|---|
| RAYMOND DEBBANE | Bought $2.7M | 8 | Feb 25, 2026 |
Recent Lexicon Pharmaceuticals Insider Transactions
| Insider | Transaction Date | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| RAYMOND DEBBANE | Feb 25, 2026 | Buy | 2,000 | $1.49 | $3,000 |
| RAYMOND DEBBANE | Feb 23, 2026 | Buy | 100,000 | $1.47 | $150,000 |
| RAYMOND DEBBANE | Feb 20, 2026 | Buy | 100,000 | $1.48 | $150,000 |
| RAYMOND DEBBANE | Feb 19, 2026 | Buy | 50,000 | $1.44 | $72,000 |
| RAYMOND DEBBANE | Feb 18, 2026 | Buy | 133,688 | $1.32 | $180,000 |
| RAYMOND DEBBANE | Feb 17, 2026 | Buy | 76,857 | $1.31 | $100,000 |
| RAYMOND DEBBANE | Feb 13, 2026 | Buy | 57,952 | $1.31 | $76,000 |
| RAYMOND DEBBANE | Feb 2, 2026 | Buy | 1,538,462 | $1.3 | $2M |
Frequently Asked Questions: Lexicon Pharmaceuticals Insider Trading
Lexicon Pharmaceuticals insiders have not reported any transactions in the past 90 days.
Insider buying is generally a stronger signal than insider selling, since insiders may sell for personal reasons (diversification, taxes) but typically buy only when they believe the stock is undervalued. AltIndex uses insider transaction patterns alongside 25+ other signals in the AI Score.
DEBBANE RAYMOND has bought the most LXRX stock in the last 2 years, with a total value of $2.7M.
According to our estimates, the total value of insider transactions for Lexicon Pharmaceuticals in the last 2 years is positive, amounting to $2.7M. This indicates that insiders have predominantly bought shares, showcasing their confidence in the company's future prospects.
